Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: post hoc analysis

Aims: To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. Patients & methods: Post hoc analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. Results: All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Conclusion: Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.

Download Full-text

P1.01-107 The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.664 ◽

2018 ◽

Vol 13 (10) ◽

pp. S505

Author(s):

X. Si ◽

L. Zhang ◽

H. Wang ◽

X. Zhang ◽

M. Wang ◽

...

Keyword(s):

Quality Of Life ◽

Randomized Control Trial ◽

Phase Iii ◽

Post Hoc Analysis ◽

Randomized Control ◽

Post Hoc ◽

The Impact

Download Full-text

A randomized, double-blind, phase III non-inferiority clinical trial to assess efficacy and safety of triamcinolone acetonide nasal spray in comparison with fluticasone propionate nasal spray in adults suffering from perennial allergic rhinitis (PAR) in Russia: a post-hoc analysis of Quality of Life

World Allergy Organization Journal ◽

10.1016/j.waojou.2020.100269 ◽

2020 ◽

Vol 13 (8) ◽

pp. 100269

Author(s):

Alexander V. Karaulov ◽

Tamara Vylegzhanina ◽

Andrey Ovchinnikov ◽

Nataiya Nenasheva ◽

Aleksandr Maslakov

Keyword(s):

Quality Of Life ◽

Clinical Trial ◽

Nasal Spray ◽

Phase Iii ◽

Efficacy And Safety ◽

Perennial Allergic Rhinitis ◽

Double Blind ◽

Post Hoc Analysis ◽

Post Hoc

Download Full-text

Triamcinolone Acetonide in the Treatment of Perennial Allergic Rhinitis: A post hoc Analysis of Quality of Life during a Phase III Study

International Archives of Allergy and Immunology ◽

10.1159/000518753 ◽

2021 ◽

pp. 1-8

Author(s):

Alexander V. Karaulov ◽

Natalia Nenasheva ◽

Yury Smolkin ◽

Aleksandr Maslakov ◽

Luiz Lucio

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

Triamcinolone Acetonide ◽

Allergic Conjunctivitis ◽

Phase Iii ◽

Treatment Groups ◽

Post Hoc Analysis ◽

Previous Diagnosis ◽

Post Hoc

Introduction: Allergic rhinitis (AR) is a disease that affects ≤24% of people in Russia, significantly impairing quality of life (QoL). Intranasal corticosteroids, such as triamcinolone acetonide (TAA), are considered effective drugs for treatment. A post hoc analysis of data (phase III NASANIF trial) examined weekly QoL changes in patients receiving TAA for the treatment of perennial AR (PAR). Methods: NASANIF (NCT03317015) was a double-blind, parallel group, multicenter, prospective, noninferiority, phase III clinical trial. Patients with PAR were randomized (1:1) to receive TAA or fluticasone propionate (FP) for 4 weeks. Here, a post hoc analysis measures QoL using a shortened Rhinoconjunctivitis Quality of Life Questionnaire (miniRQLQ). Differences in miniRQLQ score were evaluated using a mixed linear model and descriptive statistics. A subgroup analysis was performed in patients with a previous diagnosis of allergic conjunctivitis. Results: Of 260 patients eligible for randomization, 128 each completed treatment with TAA or FP. Overall and individual domain scores progressively improved and were significantly different versus baseline at week 4 in both treatment groups: LS mean difference TAA: −30.92 (95% CI [−33.01 to −28.83]), p < 0.001, and FP: −31.13 (−33.23 to −29.04), p < 0.001. In both arms of the subgroup, there was a significant reduction in eye symptoms. There was no significant difference between the TAA and FP treatment groups in any analyses. Conclusions: TAA is effective in improving overall and individual domains of QoL in patients with PAR, over 4 weeks. Patients with a previous diagnosis of allergic conjunctivitis experienced significant improvements in QoL related to the resolution of these symptoms.

Download Full-text